Last reviewed · How we verify
AGN-241751
AGN-241751 is a Sodium-activated potassium channel inhibitor Small molecule drug developed by Syndeio Biosciences, Inc. It is currently in Phase 2 development for Atrial fibrillation for stroke prevention.
AGN-241751 is a small molecule inhibitor of the sodium-activated potassium channel, Nav1.5.
AGN-241751 is a small molecule inhibitor of the sodium-activated potassium channel, Nav1.5. Used for Atrial fibrillation for stroke prevention.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | AGN-241751 |
|---|---|
| Sponsor | Syndeio Biosciences, Inc |
| Drug class | Sodium-activated potassium channel inhibitor |
| Target | Nav1.5 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
By blocking Nav1.5, AGN-241751 aims to reduce the abnormal electrical activity in the heart that can lead to atrial fibrillation. This mechanism is thought to be beneficial for patients with atrial fibrillation who are at risk of stroke.
Approved indications
- Atrial fibrillation for stroke prevention
Common side effects
- Increased risk of atrial fibrillation
Key clinical trials
- Safety and Tolerability of Zelquistinel in Normal Human Volunteers (PHASE1)
- AGN-241751 in the Treatment of Major Depressive Disorder (PHASE1, PHASE2)
- AGN-241751 in the Treatment of Major Depressive Disorder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AGN-241751 CI brief — competitive landscape report
- AGN-241751 updates RSS · CI watch RSS
- Syndeio Biosciences, Inc portfolio CI
Frequently asked questions about AGN-241751
What is AGN-241751?
How does AGN-241751 work?
What is AGN-241751 used for?
Who makes AGN-241751?
What drug class is AGN-241751 in?
What development phase is AGN-241751 in?
What are the side effects of AGN-241751?
What does AGN-241751 target?
Related
- Drug class: All Sodium-activated potassium channel inhibitor drugs
- Target: All drugs targeting Nav1.5
- Manufacturer: Syndeio Biosciences, Inc — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Atrial fibrillation for stroke prevention
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing